One of the most notable characteristics of Eli Lilly & Co.’s third quarter 2019 sales and earnings report last October was that US prescription growth of top-sellers like Trulicity and Taltz was inhibited significantly by price factors, including the fact that the Indianapolis pharma is dependent on government-insured patients for a high portion of its domestic revenues.
As Lilly reports its fourth quarter and full-year 2019 financials on 30 January, investors will be listening to hear if...








